Treatment-Resistant Mood Disorders

The introduction of monoamine oxidase inhibitors (MAOIs) and imipramine in the 1950s for depression and the introduction of lithium for bipolar disorder in the 1970s transformed the biological understanding and treatment of mood disorders for millions worldwide. Methodologically sound meta-analyses and integration of scores of randomized clinical trials show that antidepressants and mood stabilizers are superior to placebo for both the acute and long-term treatment of unipolar and bipolar mood disorders, although some question the magnitude of the effect when taking into account unpublished trials that fail to differentiate active antidepressants from placebo (Hooper and Amsterdam 1998).

The methods used to demonstrate efficacy (i.e., superiority over placebo in tightly regulated randomized clinical trials) and achieve approval by the U.S. Food and Drug Administration (FDA) require that patients respond (usually defined as a 50% improvement in a standard baseline measurement of depression) more with active treatment than with placebo. A 50% improvement over baseline, however, leaves many patients with residual symptoms. These residual symptoms, in turn, are associated with suboptimal functioning (Miller et al. 1998) and a high risk of relapse into an episode of major depression (Judd et al. 1997, 1998). Alternatively, full remission of depressive symptoms improves functioning and lowers the risk of subsequent relapse.

The goal, therefore, is full remission of the depressive episode, a goal that is achieved in no more than 30%-50% of patients in most clinical trials of antidepressants and mood stabilizers. It is notable that failure to provide full remission in all patients occurs frequently in many medical treatments (e.g., angioplasty, coronary artery bypass grafts, antihypertensive treatments, analgesics, antiparkinsonian drugs, and insulin). In the broadest sense, the failure to achieve and maintain remission can be considered the definition of treatment-resistant depression.

Treatment-Resistant Mood Disorders

Introduction

Treatment-Resistant Unipolar Depression

- Definition

- Phases of Treatment

- Depressive Subtypes and Treatment Response

- Melancholic Depression

- Atypical Depression

- Double Depression

- Psychotic Depression

- Depression With Concurrent Psychiatric Illnesses

- Anxious Depression

- Depression With Panic Attacks

- Depression With Anger Attacks

- Depression With Concurrent Personality Disorders

- Depression With Concurrent Substance Abuse

- Antidepressant Treatment Options

- Augmentation Strategies

- Thyroid augmentation

- Dopaminergic and stimulant augmentation

- Buspirone augmentation

- Venlafaxine augmentation

- Mirtazapine augmentation

- Atypical antipsychotic drug augmentation

- Anticonvulsant drug augmentation

- Benzodiazepine augmentation

- Higher-Dose Antidepressants

- Combined Antidepressant Treatments

- Combined MAOIs and TCAs

- Combined SSRIs and TCAs

- SSRI-nefazodone combination

- Switching Strategies

- Other Treatment Options

Treatment-Resistant Bipolar Disorder

- Definition

- Subtypes, Other Clinical Factors

- Practical Management

- Treatment of Bipolar Depression

- Treatments to Control Cycling

Conclusions

Multiphase Treatment Strategy for Bipolar Disorder

- Acute Phase

- Continuation Phase

- Discontinuation Phase /Maintenance Phase

Antidepressant and Antimanic Medications

Depression-Focused Psychotherapies

Psychodynamic Psychotherapies

Combined Medication and Psychotherapy

Electroconvulsive Therapy

Light Therapy

Treatment-Resistant Mood Disorders

Treatment of Mood Disorders in the Medically Ill Patient

Strategies and Tactics in the Treatment of Depression

Although many therapeutic options are available to manage resistant depression, few studies compare competing options at key decision points. The National Institute of Mental Health (NIMH) recognized the gap in knowledge and the critical need to obtain better data for clinicians to make informed decisions for both treatment-resistant unipolar depression and bipolar states (mania, rapid cycling, bipolar depression). To bridge this gap, two large NIMH studies that will evaluate competing treatment options along an algorithm are being conducted: the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (http://www.edc.gsph.pitt.edu/stepbd) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (http://www.edc.gsph.pitt.edu/stard). The results of these studies are pending. In the meantime, this chapter will critically review the available data for treating resistant mood disorders. First the data on the management of unipolar depression will be covered, and then the complex management of bipolar disorder will be reviewed.

It's easy to make a financial decision based on what you need right now, but making an informed choice will benefit you in the long run. Meet a former Red Sox pitcher who picked security over an uncertain future